Rocket


Overview
Financials
News + Filings
Key Docs
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Monopar Therapeutics (MNPR) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: " "
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: " "
07/11/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: " ",
" "
06/28/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/02/2023 SC 13G Klunzinger Jeffrey R. reports a 5.2% stake in Monopar Therapeutics Inc.
06/01/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update"
05/11/2023 8-K Quarterly results
Docs: "Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/27/2023 8-K Quarterly results
03/23/2023 10-K Annual Report for the period ended December 31, 2022
03/23/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments"
02/27/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials"
02/14/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin"
01/26/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Monopar Therapeutics Inc."
01/18/2023 8-K Quarterly results
01/05/2023 EFFECT Form EFFECT - Notice of Effectiveness:
01/04/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
12/21/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
12/12/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Monopar Therapeutics Inc."
11/16/2022 8-K Quarterly results
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 8-K Quarterly results
10/05/2022 8-K Quarterly results
08/12/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/11/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/11/2022 8-K Quarterly results
06/30/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
05/12/2022 10-Q Quarterly Report for the period ended March 31, 2022
04/29/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy